Simulations Plus, Inc. (NASDAQ: SLP) said net sales for the third quarter of 2014 increased 20.9 percent compared to the same quarter in 2013, fromUSD3.095m to USD3.741m.
Exclusing a large renewal order and one study contract that slipped from the second quarter into the third quarter (USD300,000), the company set a new record for revenues (11.2 percent increase). Gross profit was up 32.9 percent to USD3.513m, an increase of USD870,000 from USD2.643m.
Simulations Plus, Inc., is a premier developer of groundbreaking drug discovery and development simulation and modeling software, which is licensed to and used in the conduct of drug research by major pharmaceutical, biotechnology, agrochemical, and food industry companies worldwide. Simulations Plus, Inc., is headquartered in Southern California and trades on the NASDAQ Capital Market under the symbol “SLP.” For more information, see www.simulations-plus.com.